Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Novartis (NVS) announced that its late-stage study for del-desiran in myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. The stock fell on the news, marking the second pipeline setback for NVS in five days. Despite the failure, the study showed some clinical activity in secondary endpoints. NVS is evaluating the data and plans to discuss next steps with health authorities. Ionis Pharmaceuticals (IONS) shares also declined. NVS faces patent cliffs and generic competition for key
How this was made
The 30-second read
Why it matters
The failure reduces near‑term revenue expectations and may pressure guidance revisions, while the broader portfolio remains supported by other growth brands.
Market read
First‑report of a Phase III failure for a large‑cap pharma, likely prompting short‑term sell‑offs and sector‑wide caution.
What to watch
Potential for the drug to be repositioned or combined with other therapies could mitigate the setback.
Background
Novartis' pipeline includes several AOC neuromuscular candidates acquired from Avidity Biosciences; recent setbacks follow a prior late‑stage failure of pelacarsen.
Ticker impact
Novartis announced its late‑stage HARBOR study of del‑desiran failed to meet the primary endpoint, causing the stock to plunge.
downward pressure over the next few days
Phase III failure is material for a large pharma; investors react quickly to trial outcomes.
Ionis shares fell as the news of Novartis' failed del‑desiran study also impacted the licensor of pelacarsen.
slight dip in the near term
Ionis is a partner; the failure reflects on its pipeline partner but impact is secondary.
Market effects
Biotech sector may see broader risk aversion after another late‑stage failure.
European and US biotech stocks could experience short‑term weakness.
Highlights challenges in neuromuscular drug development worldwide.
Counterpoint
If secondary endpoints show meaningful signals, the market may undervalue the asset.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant reporting the trial failure.
- companyIonis Pharmaceuticals
Partner licensor of pelacarsen, whose shares also fell.
